• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Trastuzumab deruxtecan associated with lower risk of metastatic breast cancer progression

byDavid XiangandHarsh Shah
March 29, 2022
in Chronic Disease, Obstetrics, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Compared to trastuzumab emtansine, trastuzumab deruxtecan is associated with a lower risk of disease progression or death in patients with HER2-positive metastatic breast cancer.

2. Trastuzumab deruxtecan was associated with interstitial lung disease and pneumonitis.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Approximately 20% of breast cancers express HER2, and although there are HER2-targeted therapies, they are not curative and most patients will have disease progression. The current standard treatment for HER2-positive metastatic breast cancer that progresses after trastuzumab with a taxane is trastuzumab emtansine. However, trastuzumab deruxtecan has been proposed to have durable antitumor activity. There is a gap in knowledge as to understanding the efficacy of trastuzumab deruxtecan compared to currently available HER2-directed regimens such as trastuzumab emtansine. This study found that trastuzumab deruxtecan is associated with an increased reduction in risk of disease progression or death in patients with HER2-positive metastatic breast cancer. This study was limited by factors such as including patients from countries in which trastuzumab emtansine was not yet readily available. Nevertheless, this study’s findings are significant, as they demonstrate that trastuzumab deruxtecan is superior to trastuzumab emtansine in reducing the risk of progression or death in HER2-positive metastatic breast cancer.

Click to read the study in NEJM

Relevant Reading: Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

RELATED REPORTS

Trastuzumab emtansine improves outcomes in residual HER2-positive breast cancer

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer

#VisualAbstract: Increased Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer Relative to Trastuzumab Alone

In-Depth [randomized control trial]: This multicenter, open-label randomized control trial studied 524 patients. Patients who had HER2-positive unresectable or metastatic breast cancer that had progressed during or after treatment with trastuzumab and a taxane were eligible for the study. Patients with brain metastases that were symptomatic or required treatment or had previously been treated with trastuzumab emtansine were excluded from the study. The primary outcome measure was progression-free survival. Outcomes in the primary analysis were assessed via a stratified log-rank test and analysis of progression-free survival. Based on the analysis, 75.8% of patients on trastuzumab deruxtecan had no disease progression at 12 months (95% confidence interval [ CI], 69.8 to 80.7) compared to 34.1% of patients on trastuzumab emtansine (95% CI, 27.7 to 40.5). 94.1% of patients on trastuzumab deruxtecan were alive at 12 months (95% CI, 90.3 to 96.4) while 85.9% of patients on trastuzumab emtansine were alive at 12 months (95% CI, 80.9 to 89.7). Overall response in these patients was 79.7% (95% CI, 74.3 to 84.4) for trastuzumab deruxtecan and 34.2% (95% CI, 28.5 to 40.3) for trastuzumab emtansine. Drug-related interstitial lung disease or pneumonitis occurred in 10% of patients receiving trastuzumab deruxtecan and in 1.9% of patients receiving trastuzumab emtansine. The incidence of a drug-related adverse event was 98.1% with trastuzumab deruxtecan and 86.6% with trastuzumab emtansine. Overall, this study demonstrated that trastuzumab deruxtecan is superior to trastuzumab emtansine in reducing the risk of progression or death in HER2-positive metastatic breast cancer patients, and is an effective new treatment for these patients.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: HER2-negative breast cancermetastatic breast cancertrastuzumabtrastuzumab deruxtecantrastuzumab emtansine
Previous Post

Liposomal amphotericin B noninferior to standard treatment for cryptococcal meningitis

Next Post

Large vessel occlusion stroke is associated with poor prognosis in children

RelatedReports

Exercise associated with decreased breast cancer risk
Oncology

Trastuzumab emtansine improves outcomes in residual HER2-positive breast cancer

March 7, 2025
Adjuvant radiotherapy reduces recurrence of ductal carcinoma; no effect on long-term prognosis
Chronic Disease

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer

January 27, 2025
#VisualAbstract: Increased Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer Relative to Trastuzumab Alone
StudyGraphics

#VisualAbstract: Increased Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer Relative to Trastuzumab Alone

January 24, 2025
USPSTF recommends chemoprevention for women at high risk for breast cancer
Oncology

Inavolisib lengthens progression-free survival time in HER2-negative advanced breast cancer

December 11, 2024
Next Post
Combined MRI and NIH stroke scores may predict stroke prognosis

Large vessel occlusion stroke is associated with poor prognosis in children

30-Day mortality decreased in UK pediatric cardiac surgery from 2000-2010

Interatrial shunt device not effective in patients with symptomatic heart failure

#VisualAbstract: Donidalorsen reduces attacks in patients with hereditary angioedema

#VisualAbstract: Donidalorsen reduces attacks in patients with hereditary angioedema

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • New-generation antiseizure medications are better tolerated for patients with epilepsy
  • #VisualAbstract: Insulin Efsitora is Noninferior to Insulin Glargine in Type 2 Diabetes without Previous Insulin Therapy
  • Thrombolysis-to-puncture time greater than 70 minutes decreases odds of successful thrombectomy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.